Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of pharmaceutical composition containing chlorogenic acid in preparation of antiviral drugs

An antiviral drug, chlorogenic acid technology, applied in the field of medicine, can solve the problems of toxic and side effects of organs such as liver and kidney, difficult to cure chronic diseases, and low clinical efficacy, achieve high oral bioavailability, and improve oral pharmacokinetic parameters. , the effect of reducing lung index

Active Publication Date: 2021-07-23
TIANJIN UNIV OF TRADITIONAL CHINESE MEDICINE
View PDF5 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Chronic diseases caused by viral infections are difficult to cure, causing great suffering to patients, and the high cost of long-term medication brings heavy burdens to families and society
At present, the existing antiviral drugs are mainly synthetic drugs such as ribavirin, acyclovir, and oseltamivir. These drugs not only have relatively large toxic and side effects on organs such as liver and kidney, but also have strong drug resistance. , the clinical efficacy is getting lower and lower, and there is a major clinical demand for antiviral drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of pharmaceutical composition containing chlorogenic acid in preparation of antiviral drugs
  • Application of pharmaceutical composition containing chlorogenic acid in preparation of antiviral drugs
  • Application of pharmaceutical composition containing chlorogenic acid in preparation of antiviral drugs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0040] A preparation method of a pharmaceutical composition containing chlorogenic acid, comprising the steps of:

[0041] (1) Weigh soybean lecithin and the first part of chlorogenic acid, put them in a container, add ethanol aqueous solution with a volume concentration of 75%, stir at 30°C for 2h, and recover ethanol under reduced pressure (50°C, -0.08Mpa). Drying under reduced pressure, crushing the dried solids, and passing through a No. 5 sieve to obtain the chlorogenic acid phospholipid complex;

[0042] (2) Weighing the second portion of chlorogenic acid and the chlorogenic acid phospholipid complex obtained in step (1), mixing them, and stirring evenly to obtain a pharmaceutical composition containing chlorogenic acid.

[0043] The mass ratio of soybean lecithin, the first chlorogenic acid and 75% ethanol aqueous solution is 5:5:1000.

[0044] The mass ratio of the second chlorogenic acid to the chlorogenic acid-phospholipid complex obtained in step (1) is 1:2.

[00...

Embodiment 2

[0047] A preparation method of a pharmaceutical composition containing chlorogenic acid, comprising the steps of:

[0048] (1) Weigh dimyristoylphosphatidylethanolamine and the first part of chlorogenic acid, put them in a container, add ethanol aqueous solution with a volume concentration of 90%, stir at 35°C for 1h, and reduce pressure (50°C, -0.08Mpa) Recover ethanol, dry the solid under reduced pressure, pulverize the dried solid, and pass through a No. 6 sieve to obtain the chlorogenic acid phospholipid complex;

[0049](2) Weighing the second portion of chlorogenic acid and the chlorogenic acid-phospholipid complex obtained in step (1), mixing them, and stirring evenly to obtain a pharmaceutical composition containing chlorogenic acid.

[0050] The mass ratio of dimyristoylphosphatidylethanolamine, the first part of chlorogenic acid and the aqueous ethanol solution with a volume concentration of 90% is 10:2:4000.

[0051] The mass ratio of the second chlorogenic acid to...

Embodiment 3

[0053] A preparation method of a pharmaceutical composition containing chlorogenic acid, comprising the steps of:

[0054] (1) Weigh dimyristoylphosphatidylglycerol and the first part of chlorogenic acid, put them in a container, add an aqueous ethanol solution with a volume concentration of 80%, stir at 20°C for 2h, and reduce pressure (50°C, -0.08Mpa) Recover ethanol, dry the solid under reduced pressure, pulverize the dried solid, and pass through a No. 4 sieve to obtain the chlorogenic acid phospholipid complex;

[0055] (2) Weighing the second portion of chlorogenic acid and the chlorogenic acid-phospholipid complex obtained in step (1), mixing them in an equal increment method, and stirring evenly to obtain a pharmaceutical composition containing chlorogenic acid.

[0056] The mass ratio of dimyristoylphosphatidylglycerol, the first chlorogenic acid, and 80% ethanol aqueous solution is 4:10:2000.

[0057] The mass ratio of the second chlorogenic acid to the chlorogenic ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of a pharmaceutical composition containing chlorogenic acid in preparation of antiviral drugs. Experiments prove that the pharmaceutical composition containing the chlorogenic acid can resist viruses. The pharmaceutical composition containing the chlorogenic acid is high in oral bioavailability, and oral drug kinetic parameters of the raw material chlorogenic acid are improved. The pharmaceutical composition containing the chlorogenic acid can obviously inhibit weight loss of virus infected mice, reduce lung indexes, inhibit lung tissue inflammatory factors, resist inflammatory storm, reduce the virus load of lung tissues and resist damage of influenza A viruses and human coronavirus to lungs.

Description

technical field [0001] The invention relates to the field of medicine, in particular to the application of a pharmaceutical composition containing chlorogenic acid in the preparation of antiviral drugs. Background technique [0002] Chlorogenic acid (CGA) widely exists in medicinal plants, mainly in Lonicera and Eucommia, such as honeysuckle and Eucommia. The solubility of chlorogenic acid in water at 25°C is 4%, and the solubility in hot water is even greater. It is easily soluble in ethanol and acetone, slightly soluble in ethyl acetate, and hardly soluble in chloroform and ether. [0003] At present, studies have shown that chlorogenic acid has the effect of preventing and treating lung injury, can inhibit the increase of myeloperoxidase activity in lung tissue caused by lipopolysaccharide and the expression of polymorphonuclear leukocytes in alveolar lavage fluid, and significantly reduce the lung damage. Inducible nitric oxide synthase activity in tissues; in addition,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/216A61K47/24A61P31/12A61P31/16A61P31/14
CPCA61K31/216A61K47/24A61P31/12A61P31/16A61P31/14Y02A50/30
Inventor 高秀梅王涛姚荣妹刘志东吕彬祁东利郭金赫杜耀东胡利民
Owner TIANJIN UNIV OF TRADITIONAL CHINESE MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com